News

Published on 20 Jun 2024 on Simply Wall St. · via Yahoo Finance

Nurix Therapeutics, Inc. (NASDAQ:NRIX) is a favorite amongst institutional...


Article preview image

Key Insights

Significantly high institutional ownership implies Nurix Therapeutics' stock price is sensitive to their trading actionsThe top 11 shareholders own 51% of the companyOwnership research along with analyst forecasts data help provide a good understanding of opportunities in a stock

Every investor in Nurix Therapeutics, Inc. (NASDAQ:NRIX) should be aware of the most powerful shareholder groups. We can see that institutions own the lion's share in the company with 66% ownership. Put another way, the group faces the maximum upside potential (or downside risk).

NASDAQ.NRIX price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Sign up for free
Related News
Cathie Wood's Latest Shake-up: Dumps Palantir And Jack Dorsey's Block Along With...

On Monday, Cathie Wood-led Ark Invest made significant trades, with the most notable being the tr...

Benzinga 5 Nov 2024

Nurix therapeutics CFO Hans van Houte sells $57,554 in stock By Investing.com

SAN FRANCISCO—Hans van Houte, Chief Financial Officer of Nurix Therapeutics, Inc. (NASDAQ:NRIX),...

Investing.com 31 Oct 2024

Nurix therapeutics chief legal officer sells shares worth over $101k By...

SAN FRANCISCO—Christine Ring, Chief Legal Officer at Nurix Therapeutics, Inc. (NASDAQ:NRIX),...

Investing.com 31 Oct 2024

Nurix Therapeutics, Inc. (NASDAQ:NRIX) is a favorite amongst institutional...

Key Insights Significantly high institutional ownership implies Nurix Therapeutics' stock price i...

Simply Wall St. · via Yahoo Finance 20 Jun 2024

Insider Sale: CFO Houte Van Sells 20,000 Shares of Nurix Therapeutics Inc (NRIX)

On June 20, 2024, Houte Van, Chief Financial Officer of Nurix Therapeutics Inc (NASDAQ:NRIX), exe...

GuruFocus.com · via Yahoo Finance 20 Jun 2024

Roche's (RHHBY) Combination Therapy Meets Goal in Lymphoma Study

Roche Holding AG RHHBY announced that the late-stage study evaluating its marketed drug, Columvi ...

Zacks via Yahoo Finance 15 Apr 2024

Nurix Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering By Investing.com

Nurix Therapeutics, Inc. (Nasdaq: NRIX) today announced the pricing of its upsized underwritten...

Investing.com 12 Apr 2024

Nurix Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering

Nurix Therapeutics, Inc. ( Nasdaq : NRIX) today announced the pricing of its upsized underwritten...

Investing.com 12 Apr 2024

ALX Oncology (ALXO) Posts Upbeat Results From Lymphoma Study

ALX Oncology Holdings Inc. ALXO reported positive results from an ongoing phase I/II investigator...

Zacks via Yahoo Finance 11 Apr 2024

RBC Capital ups Nurix share price target post-Q1 earnings By Investing.com

On Thursday, RBC Capital increased its share price target on Nurix Therapeutics Inc. (NASDAQ:NRIX...

Investing.com 11 Apr 2024